Efficacy of MK615 for the treatment of patients with liver disorders

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 31

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

526

HTML

4472

Figures (1-4)

272

Tables (1-3)

227

Sum=5497

Aug 21, 2012 (publication date) through Feb 24, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Aug 21, 2012; 18(31): 4118-4126
Published online Aug 21, 2012. doi: 10.3748/wjg.v18.i31.4118

Table 2 Response rate of MK615 therapy in patients with liver disorder (%)

NAFLD: Non-alcoholic fatty liver disease; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.

Citation: Hokari A, Ishikawa T, Tajiri H, Matsuda T, Ishii O, Matsumoto N, Okuse C, Takahashi H, Kurihara T, Kawahara KI, Maruyama I, Zeniya M. Efficacy of MK615 for the treatment of patients with liver disorders. World J Gastroenterol 2012; 18(31): 4118-4126
URL: https://www.wjgnet.com/1007-9327/full/v18/i31/4118.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i31.4118